{"entity":{"id":"molecular-partners","kind":"company","name":"Molecular Partners","aka":["Molecular Partners AG"],"tldr":"Molecular Partners is a Switzerland-based radiopharmaceutical company running 2 late-stage cancer trials of [212Pb]Pb-MP0712 and MP0533 with Obinutuzumab pretreatment in neuroendocrine tumours, non-small-cell lung cancer and pancreatic ductal adenocarcinoma.","summary":"Molecular Partners, based in Zurich, Switzerland, is a radiopharmaceutical company. Molecular Partners develops DARPin (Designed Ankyrin Repeat Protein) therapeutics, including radiopharmaceuticals and immune cell engagers, mainly for cancer. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing [212Pb]Pb-MP0712 and MP0533 with Obinutuzumab pretreatment in neuroendocrine tumours, non-small-cell lung cancer, pancreatic ductal adenocarcinoma, bladder & urothelial cancer and acute myeloid leukaemia. The largest, NCT05673057 (Study of MP0533 in Patients Acute Myeloid Leukaemia or Myelodysplastic Syndrome), plans to enrol 249 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Molecular_Partners","links":[{"label":"Official website","url":"https://www.molecularpartners.com"},{"label":"ClinicalTrials.gov: trials led by Molecular Partners","url":"https://clinicaltrials.gov/search?lead=Molecular%20Partners%20AG"},{"label":"Pipeline page","url":"https://www.molecularpartners.com/pipeline"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["neuroendocrine","nsclc","pancreatic","urothelial","aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04115306","nct05673057","nct07278479"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Zurich","country":"CH","companyType":"radiopharma","website":"https://www.molecularpartners.com","founded":2004,"stage":"public","investors":[],"funding":[]},"route":"/companies/molecular-partners/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"trial":[{"id":"nct04115306","kind":"trial","name":"Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer","route":"/trials/nct04115306/"},{"id":"nct07278479","kind":"trial","name":"Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors","route":"/trials/nct07278479/"},{"id":"nct05673057","kind":"trial","name":"Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome","route":"/trials/nct05673057/"}]}}